



Express Mail No. EV 473 972 475 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dwyer & Delmedico

Confirmation No.: 2635

Application No.: 10/671,316

Art Unit: 1648

Filed: September 24, 2003

Examiner: Jeffrey S. Parkin, Ph.D.

For: METHOD FOR PRODUCTION OF
ANTIVIRALS BY USE OF HIV-
DERIVED HRI PEPTIDES, AND
TRIMERS FORMED THEREFROM

Attorney 902445-999122
Docket No: (formerly TRM-002)

TRANSMITTAL OF FORMAL DRAWINGS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Sir:

Transmitted herewith are replacement formal drawing sheets in connection with the above-identified patent application. Specifically, enclosed are 4 sheets of drawings (Figures 1-5) offered as direct replacements for the corresponding drawings previously filed on September 24, 2003.

Applicant respectfully requests entry of the enclosed replacement formal drawing sheets into the file of the above-identified application.

It is believed that no fee is required for filing this transmittal. In the event a fee is required, please charge the required fee to Jones Day Deposit Account No. 50-3013.


Respectfully submitted,

Date December 13, 2007

by *[Signature]* Reg. No. 51,036
Laura A. Coruzzi Reg. No. 30,742 30,742
Laura A. Coruzzi (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosure



Notice to Comply

Application No.

10/671,316

Applicant(s)

Dwyer, J., et al.

Examiner

Jeffrey S. Parkin

Art Unit

1648

Paper No.

06/11/2007

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Applicants are reminded that sequences appearing in the specification and/or drawings (see Figs. 1-3) must be identified by a sequence identifier (SEQ ID NO.:) in accordance with 37 C.F.R. 1.821(d). Sequence identifiers for sequences appearing in the drawings may appear in the Brief Description of the Drawings. Applicant must provide appropriate amendments to the specification and/or drawings inserting the required sequence identifiers. Extensive amendments may necessitate the submission of a substitute specification and drawings.

Applicant May Need to Provide:

- ☒ An substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
 - For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
 - Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov.
- To Download Patentin Software, visit <http://www.uspto.gov/web/patents/software.htm>.

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY